Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTHZBM4X)

• DOT Name: Dystonin (DST)
• Synonyms: 230 kDa bullous pemphigoid antigen; 230/240 kDa bullous pemphigoid antigen; Bullous pemphigoid antigen 1; BPA; Bullous pemphigoid antigen; Dystonia musculorum protein; Hemidesmosomal plaque protein
• Gene Name: DST
• Related Disease:
  Hereditary sensory and autonomic neuropathy type 6
  Neoplasm
  Adenocarcinoma
  Advanced cancer
  Alzheimer disease
  Autism spectrum disorder
  Autoimmune disease
  Colon cancer
  Colon carcinoma
  Colonic neoplasm
  Dementia
  Depression
  Dystonia
  Epidermolysis bullosa simplex
  Epidermolysis bullosa simplex 3, localized or generalized intermediate, with BP230 deficiency
  Head-neck squamous cell carcinoma
  High blood pressure
  Major depressive disorder
  Metabolic disorder
  Nasopharyngeal carcinoma
  Non-insulin dependent diabetes
  Obesity
  Oral cancer
  Schizophrenia
  Skin disease
  Systemic lupus erythematosus
  Tuberculosis
  Type-1/2 diabetes
  Uterine fibroids
  Bullous pemphigoid
  Hereditary sensory and autonomic neuropathy
  Pancreatic cancer
  Epidermolysis bullosa
  Multiple sclerosis
  Nephropathy
  Adult glioblastoma
  Breast cancer
  Breast carcinoma
  Bulimia nervosa
  Glioblastoma multiforme
  Melanoma
  Nervous system disease
  Parkinson disease
  Prostate cancer
  Prostate carcinoma
  Rheumatoid arthritis
  Squamous cell carcinoma
• UniProt ID: DYST_HUMAN
• PDB ID: 3GJO; 7OLG
• Pfam ID: PF00307 ; PF13499 ; PF02187 ; PF00681 ; PF17902 ; PF00435 ; PF18373 ; PF21019 ; PF21020 ; PF21097
• Sequence:
  MAGYLSPAAYLYVEEQEYLQAYEDVLERYKDERDKVQKKTFTKWINQHLMKVRKHVNDLY
  EDLRDGHNLISLLEVLSGDTLPREKGRMRFHRLQNVQIALDYLKRRQVKLVNIRNDDITD
  GNPKLTLGLIWTIILHFQISDIHVTGESEDMSAKERLLLWTQQATEGYAGIRCENFTTCW
  RDGKLFNAIIHKYRPDLIDMNTVAVQSNLANLEHAFYVAEKIGVIRLLDPEDVDVSSPDE
  KSVITYVSSLYDAFPKVPEGGEGIGANDVEVKWIEYQNMVNYLIQWIRHHVTTMSERTFP
  NNPVELKALYNQYLQFKETEIPPKETEKSKIKRLYKLLEIWIEFGRIKLLQGYHPNDIEK
  EWGKLIIAMLEREKALRPEVERLEMLQQIANRVQRDSVICEDKLILAGNALQSDSKRLES
  GVQFQNEAEIAGYILECENLLRQHVIDVQILIDGKYYQADQLVQRVAKLRDEIMALRNEC
  SSVYSKGRILTTEQTKLMISGITQSLNSGFAQTLHPSLTSGLTQSLTPSLTSSSMTSGLS
  SGMTSRLTPSVTPAYTPGFPSGLVPNFSSGVEPNSLQTLKLMQIRKPLLKSSLLDQNLTE
  EEINMKFVQDLLNWVDEMQVQLDRTEWGSDLPSVESHLENHKNVHRAIEEFESSLKEAKI
  SEIQMTAPLKLTYAEKLHRLESQYAKLLNTSRNQERHLDTLHNFVSRATNELIWLNEKEE
  EEVAYDWSERNTNIARKKDYHAELMRELDQKEENIKSVQEIAEQLLLENHPARLTIEAYR
  AAMQTQWSWILQLCQCVEQHIKENTAYFEFFNDAKEATDYLRNLKDAIQRKYSCDRSSSI
  HKLEDLVQESMEEKEELLQYKSTIANLMGKAKTIIQLKPRNSDCPLKTSIPIKAICDYRQ
  IEITIYKDDECVLANNSHRAKWKVISPTGNEAMVPSVCFTVPPPNKEAVDLANRIEQQYQ
  NVLTLWHESHINMKSVVSWHYLINEIDRIRASNVASIKTMLPGEHQQVLSNLQSRFEDFL
  EDSQESQVFSGSDITQLEKEVNVCKQYYQELLKSAEREEQEESVYNLYISEVRNIRLRLE
  NCEDRLIRQIRTPLERDDLHESVFRITEQEKLKKELERLKDDLGTITNKCEEFFSQAAAS
  SSVPTLRSELNVVLQNMNQVYSMSSTYIDKLKTVNLVLKNTQAAEALVKLYETKLCEEEA
  VIADKNNIENLISTLKQWRSEVDEKRQVFHALEDELQKAKAISDEMFKTYKERDLDFDWH
  KEKADQLVERWQNVHVQIDNRLRDLEGIGKSLKYYRDTYHPLDDWIQQVETTQRKIQENQ
  PENSKTLATQLNQQKMLVSEIEMKQSKMDECQKYAEQYSATVKDYELQTMTYRAMVDSQQ
  KSPVKRRRMQSSADLIIQEFMDLRTRYTALVTLMTQYIKFAGDSLKRLEEEEKSLEEEKK
  EHVEKAKELQKWVSNISKTLKDAEKAGKPPFSKQKISSEEISTKKEQLSEALQTIQLFLA
  KHGDKMTDEERNELEKQVKTLQESYNLLFSESLKQLQESQTSGDVKVEEKLDKVIAGTID
  QTTGEVLSVFQAVLRGLIDYDTGIRLLETQLMISGLISPELRKCFDLKDAKSHGLIDEQI
  LCQLKELSKAKEIISAASPTTIPVLDALAQSMITESMAIKVLEILLSTGSLVIPATGEQL
  TLQKAFQQNLVSSALFSKVLERQNMCKDLIDPCTSEKVSLIDMVQRSTLQENTGMWLLPV
  RPQEGGRITLKCGRNISILRAAHEGLIDRETMFRLLSAQLLSGGLINSNSGQRMTVEEAV
  REGVIDRDTASSILTYQVQTGGIIQSNPAKRLTVDEAVQCDLITSSSALLVLEAQRGYVG
  LIWPHSGEIFPTSSSLQQELITNELAYKILNGRQKIAALYIPESSQVIGLDAAKQLGIID
  NNTASILKNITLPDKMPDLGDLEACKNARRWLSFCKFQPSTVHDYRQEEDVFDGEEPVTT
  QTSEETKKLFLSYLMINSYMDANTGQRLLLYDGDLDEAVGMLLEGCHAEFDGNTAIKECL
  DVLSSSGVFLNNASGREKDECTATPSSFNKCHCGEPEHEETPENRKCAIDEEFNEMRNTV
  INSEFSQSGKLASTISIDPKVNSSPSVCVPSLISYLTQTELADISMLRSDSENILTNYEN
  QSRVETNERANECSHSKNIQNFPSDLIENPIMKSKMSKFCGVNETENEDNTNRDSPIFDY
  SPRLSALLSHDKLMHSQGSFNDTHTPESNGNKCEAPALSFSDKTMLSGQRIGEKFQDQFL
  GIAAINISLPGEQYGQKSLNMISSNPQVQYHNDKYISNTSGEDEKTHPGFQQMPEDKEDE
  SEIEEYSCAVTPGGDTDNAIVSLTCATPLLDETISASDYETSLLNDQQNNTGTDTDSDDD
  FYDTPLFEDDDHDSLLLDGDDRDCLHPEDYDTLQEENDETASPADVFYDVSKENENSMVP
  QGAPVGSLSVKNKAHCLQDFLMDVEKDELDSGEKIHLNPVGSDKVNGQSLETGSERECTN
  ILEGDESDSLTDYDIVGGKESFTASLKFDDSGSWRGRKEEYVTGQEFHSDTDHLDSMQSE
  ESYGDYIYDSNDQDDDDDDGIDEEGGGIRDENGKPRCQNVAEDMDIQLCASILNENSDEN
  ENINTMILLDKMHSCSSLEKQQRVNVVQLASPSENNLVTEKSNLPEYTTEIAGKSKENLL
  NHEMVLKDVLPPIIKDTESEKTFGPASISHDNNNISSTSELGTDLANTKVKLIQGSELPE
  LTDSVKGKDEYFKNMTPKVDSSLDHIICTEPDLIGKPAEESHLSLIASVTDKDPQGNGSD
  LIKGRDGKSDILIEDETSIQKMYLGEGEVLVEGLVEEENRHLKLLPGKNTRDSFKLINSQ
  FPFPQITNNEELNQKGSLKKATVTLKDEPNNLQIIVSKSPVQFENLEEIFDTSVSKEISD
  DITSDITSWEGNTHFEESFTDGPEKELDLFTYLKHCAKNIKAKDVAKPNEDVPSHVLITA
  PPMKEHLQLGVNNTKEKSTSTQKDSPLNDMIQSNDLCSKESISGGGTEISQFTPESIEAT
  LSILSRKHVEDVGKNDFLQSERCANGLGNDNSSNTLNTDYSFLEINNKKERIEQQLPKEQ
  ALSPRSQEKEVQIPELSQVFVEDVKDILKSRLKEGHMNPQEVEEPSACADTKILIQNLIK
  RITTSQLVNEASTVPSDSQMSDSSGVSPMTNSSELKPESRDDPFCIGNLKSELLLNILKQ
  DQHSQKITGVFELMRELTHMEYDLEKRGITSKVLPLQLENIFYKLLADGYSEKIEHVGDF
  NQKACSTSEMMEEKPHILGDIKSKEGNYYSPNLETVKEIGLESSTVWASTLPRDEKLKDL
  CNDFPSHLECTSGSKEMASGDSSTEQFSSELQQCLQHTEKMHEYLTLLQDMKPPLDNQES
  LDNNLEALKNQLRQLETFELGLAPIAVILRKDMKLAEEFLKSLPSDFPRGHVEELSISHQ
  SLKTAFSSLSNVSSERTKQIMLAIDSEMSKLAVSHEEFLHKLKSFSDWVSEKSKSVKDIE
  IVNVQDSEYVKKRLEFLKNVLKDLGHTKMQLETTAFDVQFFISEYAQDLSPNQSKQLLRL
  LNTTQKCFLDVQESVTTQVERLETQLHLEQDLDDQKIVAERQQEYKEKLQGICDLLTQTE
  NRLIGHQEAFMIGDGTVELKKYQSKQEELQKDMQGSAQALAEVVKNTENFLKENGEKLSQ
  EDKALIEQKLNEAKIKCEQLNLKAEQSKKELDKVVTTAIKEETEKVAAVKQLEESKTKIE
  NLLDWLSNVDKDSERAGTKHKQVIEQNGTHFQEGDGKSAIGEEDEVNGNLLETDVDGQVG
  TTQENLNQQYQKVKAQHEKIISQHQAVIIATQSAQVLLEKQGQYLSPEEKEKLQKNMKEL
  KVHYETALAESEKKMKLTHSLQEELEKFDADYTEFEHWLQQSEQELENLEAGADDINGLM
  TKLKRQKSFSEDVISHKGDLRYITISGNRVLEAAKSCSKRDGGKVDTSATHREVQRKLDH
  ATDRFRSLYSKCNVLGNNLKDLVDKYQHYEDASCGLLAGLQACEATASKHLSEPIAVDPK
  NLQRQLEETKALQGQISSQQVAVEKLKKTAEVLLDARGSLLPAKNDIQKTLDDIVGRYED
  LSKSVNERNEKLQITLTRSLSVQDGLDEMLDWMGNVESSLKEQGQVPLNSTALQDIISKN
  IMLEQDIAGRQSSINAMNEKVKKFMETTDPSTASSLQAKMKDLSARFSEASHKHKETLAK
  MEELKTKVELFENLSEKLQTFLETKTQALTEVDVPGKDVTELSQYMQESTSEFLEHKKHL
  EVLHSLLKEISSHGLPSDKALVLEKTNNLSKKFKEMEDTIKEKKEAVTSCQEQLDAFQVL
  VKSLKSWIKETTKKVPIVQPSFGAEDLGKSLEDTKKLQEKWSLKTPEIQKVNNSGISLCN
  LISAVTTPAKAIAAVKSGGAVLNGEGTATNTEEFWANKGLTSIKKDMTDISHGYEDLGLL
  LKDKIAELNTKLSKLQKAQEESSAMMQWLQKMNKTATKWQQTPAPTDTEAVKTQVEQNKS
  FEAELKQNVNKVQELKDKLTELLEENPDTPEAPRWKQMLTEIDSKWQELNQLTIDRQQKL
  EESSNNLTQFQTVEAQLKQWLVEKELMVSVLGPLSIDPNMLNTQRQQVQILLQEFATRKP
  QYEQLTAAGQGILSRPGEDPSLRGIVKEQLAAVTQKWDSLTGQLSDRCDWIDQAIVKSTQ
  YQSLLRSLSDKLSDLDNKLSSSLAVSTHPDAMNQQLETAQKMKQEIQQEKKQIKVAQALC
  EDLSALVKEEYLKAELSRQLEGILKSFKDVEQKAENHVQHLQSACASSHQFQQMSRDFQA
  WLDTKKEEQNKSHPISAKLDVLESLIKDHKDFSKTLTAQSHMYEKTIAEGENLLLKTQGS
  EKAALQLQLNTIKTNWDTFNKQVKERENKLKESLEKALKYKEQVETLWPWIDKCQNNLEE
  IKFCLDPAEGENSIAKLKSLQKEMDQHFGMVELLNNTANSLLSVCEIDKEVVTDENKSLI
  QKVDMVTEQLHSKKFCLENMTQKFKEFQEVSKESKRQLQCAKEQLDIHDSLGSQAYSNKY
  LTMLQTQQKSLQALKHQVDLAKRLAQDLVVEASDSKGTSDVLLQVETIAQEHSTLSQQVD
  EKCSFLETKLQGIGHFQNTIREMFSQFAEFDDELDSMAPVGRDAETLQKQKETIKAFLKK
  LEALMASNDNANKTCKMMLATEETSPDLVGIKRDLEALSKQCNKLLDRAQAREEQVEGTI
  KRLEEFYSKLKEFSILLQKAEEHEESQGPVGMETETINQQLNMFKVFQKEEIEPLQGKQQ
  DVNWLGQGLIQSAAKSTSTQGLEHDLDDVNARWKTLNKKVAQRAAQLQEALLHCGRFQDA
  LESLLSWMVDTEELVANQKPPSAEFKVVKAQIQEQKLLQRLLDDRKSTVEVIKREGEKIA
  TTAEPADKVKILKQLSLLDSRWEALLNKAETRNRQLEGISVVAQQFHETLEPLNEWLTTI
  EKRLVNCEPIGTQASKLEEQIAQHKALEDDIINHNKHLHQAVSIGQSLKVLSSREDKDMV
  QSKLDFSQVWYIEIQEKSHSRSELLQQALCNAKIFGEDEVELMNWLNEVHDKLSKLSVQD
  YSTEGLWKQQSELRVLQEDILLRKQNVDQALLNGLELLKQTTGDEVLIIQDKLEAIKARY
  KDITKLSTDVAKTLEQALQLARRLHSTHEELCTWLDKVEVELLSYETQVLKGEEASQAQM
  RPKELKKEAKNNKALLDSLNEVSSALLELVPWRAREGLEKMVAEDNERYRLVSDTITQKV
  EEIDAAILRSQQFDQAADAELSWITETEKKLMSLGDIRLEQDQTSAQLQVQKTFTMEILR
  HKDIIDDLVKSGHKIMTACSEEEKQSMKKKLDKVLKNYDTICQINSERYLQLERAQSLVN
  QFWETYEELWPWLTETQSIISQLPAPALEYETLRQQQEEHRQLRELIAEHKPHIDKMNKT
  GPQLLELSPGEGFSIQEKYVAADTLYSQIKEDVKKRAVALDEAISQSTQFHDKIDQILES
  LERIVERLRQPPSISAEVEKIKEQISENKNVSVDMEKLQPLYETLKQRGEEMIARSGGTD
  KDISAKAVQDKLDQMVFIWENIHTLVEEREAKLLDVMELAEKFWCDHMSLIVTIKDTQDF
  IRDLEDPGIDPSVVKQQQEAAETIREEIDGLQEELDIVINLGSELIAACGEPDKPIVKKS
  IDELNSAWDSLNKAWKDRIDKLEEAMQAAVQYQDGLQAVFDWVDIAGGKLASMSPIGTDL
  ETVKQQIEELKQFKSEAYQQQIEMERLNHQAELLLKKVTEESDKHTVQDPLMELKLIWDS
  LEERIINRQHKLEGALLALGQFQHALDELLAWLTHTEGLLSEQKPVGGDPKAIEIELAKH
  HVLQNDVLAHQSTVEAVNKAGNDLIESSAGEEASNLQNKLEVLNQRWQNVLEKTEQRKQQ
  LDGALRQAKGFHGEIEDLQQWLTDTERHLLASKPLGGLPETAKEQLNVHMEVCAAFEAKE
  ETYKSLMQKGQQMLARCPKSAETNIDQDINNLKEKWESVETKLNERKTKLEEALNLAMEF
  HNSLQDFINWLTQAEQTLNVASRPSLILDTVLFQIDEHKVFANEVNSHREQIIELDKTGT
  HLKYFSQKQDVVLIKNLLISVQSRWEKVVQRLVERGRSLDDARKRAKQFHEAWSKLMEWL
  EESEKSLDSELEIANDPDKIKTQLAQHKEFQKSLGAKHSVYDTTNRTGRSLKEKTSLADD
  NLKLDDMLSELRDKWDTICGKSVERQNKLEEALLFSGQFTDALQALIDWLYRVEPQLAED
  QPVHGDIDLVMNLIDNHKAFQKELGKRTSSVQALKRSARELIEGSRDDSSWVKVQMQELS
  TRWETVCALSISKQTRLEAALRQAEEFHSVVHALLEWLAEAEQTLRFHGVLPDDEDALRT
  LIDQHKEFMKKLEEKRAELNKATTMGDTVLAICHPDSITTIKHWITIIRARFEEVLAWAK
  QHQQRLASALAGLIAKQELLEALLAWLQWAETTLTDKDKEVIPQEIEEVKALIAEHQTFM
  EEMTRKQPDVDKVTKTYKRRAADPSSLQSHIPVLDKGRAGRKRFPASSLYPSGSQTQIET
  KNPRVNLLVSKWQQVWLLALERRRKLNDALDRLEELREFANFDFDIWRKKYMRWMNHKKS
  RVMDFFRRIDKDQDGKITRQEFIDGILSSKFPTSRLEMSAVADIFDRDGDGYIDYYEFVA
  ALHPNKDAYKPITDADKIEDEVTRQVAKCKCAKRFQVEQIGDNKYRFFLGNQFGDSQQLR
  LVRILRSTVMVRVGGGWMALDEFLVKNDPCRVHHHGSKMLRSESNSSITTTQPTIAKGRT
  NMELREKFILADGASQGMAAFRPRGRRSRPSSRGASPNRSTSVSSQAAQAASPQVPATTT
  PKGTPIQGSKLRLPGYLSGKGFHSGEDSGLITTAAARVRTQFADSKKTPSRPGSRAGSKA
  GSRASSRRGSDASDFDISEIQSVCSDVETVPQTHRPTPRAGSRPSTAKPSKIPTPQRKSP
  ASKLDKSSKR
• Function: Cytoskeletal linker protein. Acts as an integrator of intermediate filaments, actin and microtubule cytoskeleton networks. Required for anchoring either intermediate filaments to the actin cytoskeleton in neural and muscle cells or keratin-containing intermediate filaments to hemidesmosomes in epithelial cells. The proteins may self-aggregate to form filaments or a two-dimensional mesh. Regulates the organization and stability of the microtubule network of sensory neurons to allow axonal transport. Mediates docking of the dynein/dynactin motor complex to vesicle cargos for retrograde axonal transport through its interaction with TMEM108 and DCTN1; [Isoform 3]: Plays a structural role in the assembly of hemidesmosomes of epithelial cells; anchors keratin-containing intermediate filaments to the inner plaque of hemidesmosomes. Required for the regulation of keratinocyte polarity and motility; mediates integrin ITGB4 regulation of RAC1 activity.; [Isoform 6]: Required for bundling actin filaments around the nucleus; [Isoform 7]: Regulates the organization and stability of the microtubule network of sensory neurons to allow axonal transport.
• Tissue Specificity: Isoform 1 is expressed in myoblasts (at protein level). Isoform 3 is expressed in the skin. Isoform 6 is expressed in the brain. Highly expressed in skeletal muscle and cultured keratinocytes.
• Reactome Pathway:
  RHOU GTPase cycle (R-HSA-9013420)
  RHOV GTPase cycle (R-HSA-9013424)
  RND3 GTPase cycle (R-HSA-9696264)
  RND2 GTPase cycle (R-HSA-9696270)
  RND1 GTPase cycle (R-HSA-9696273)
  Type I hemidesmosome assembly (R-HSA-446107)

Molecular Interaction Atlas (MIA) of This DOT

47 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Hereditary sensory and autonomic neuropathy type 6	DIS0MINU	Definitive	Autosomal recessive	[1]
Neoplasm	DISZKGEW	Definitive	Biomarker	[2]
Adenocarcinoma	DIS3IHTY	Strong	Altered Expression	[3]
Advanced cancer	DISAT1Z9	Strong	Biomarker	[4]
Alzheimer disease	DISF8S70	Strong	Biomarker	[5]
Autism spectrum disorder	DISXK8NV	Strong	Biomarker	[6]
Autoimmune disease	DISORMTM	Strong	Altered Expression	[7]
Colon cancer	DISVC52G	Strong	Biomarker	[8]
Colon carcinoma	DISJYKUO	Strong	Biomarker	[8]
Colonic neoplasm	DISSZ04P	Strong	Biomarker	[9]
Dementia	DISXL1WY	Strong	Biomarker	[10]
Depression	DIS3XJ69	Strong	Biomarker	[11]
Dystonia	DISJLFGW	Strong	Genetic Variation	[12]
Epidermolysis bullosa simplex	DIS2CZ6X	Strong	Genetic Variation	[13]
Epidermolysis bullosa simplex 3, localized or generalized intermediate, with BP230 deficiency	DISUXSR3	Strong	Autosomal recessive	[14]
Head-neck squamous cell carcinoma	DISF7P24	Strong	Biomarker	[15]
High blood pressure	DISY2OHH	Strong	Genetic Variation	[16]
Major depressive disorder	DIS4CL3X	Strong	Biomarker	[17]
Metabolic disorder	DIS71G5H	Strong	Biomarker	[18]
Nasopharyngeal carcinoma	DISAOTQ0	Strong	Biomarker	[19]
Non-insulin dependent diabetes	DISK1O5Z	Strong	Genetic Variation	[16]
Obesity	DIS47Y1K	Strong	Biomarker	[20]
Oral cancer	DISLD42D	Strong	Biomarker	[2]
Schizophrenia	DISSRV2N	Strong	Genetic Variation	[21]
Skin disease	DISDW8R6	Strong	Biomarker	[22]
Systemic lupus erythematosus	DISI1SZ7	Strong	Biomarker	[23]
Tuberculosis	DIS2YIMD	Strong	Genetic Variation	[24]
Type-1/2 diabetes	DISIUHAP	Strong	Biomarker	[5]
Uterine fibroids	DISBZRMJ	Strong	Biomarker	[25]
Bullous pemphigoid	DISOJLKV	moderate	Biomarker	[26]
Hereditary sensory and autonomic neuropathy	DIS2VOAM	moderate	Genetic Variation	[12]
Pancreatic cancer	DISJC981	moderate	Biomarker	[27]
Epidermolysis bullosa	DISVOTZQ	Disputed	Genetic Variation	[28]
Multiple sclerosis	DISB2WZI	Disputed	Genetic Variation	[29]
Nephropathy	DISXWP4P	Disputed	Biomarker	[30]
Adult glioblastoma	DISVP4LU	Limited	Biomarker	[31]
Breast cancer	DIS7DPX1	Limited	Biomarker	[32]
Breast carcinoma	DIS2UE88	Limited	Biomarker	[32]
Bulimia nervosa	DISGQ59Y	Limited	Biomarker	[33]
Glioblastoma multiforme	DISK8246	Limited	Biomarker	[31]
Melanoma	DIS1RRCY	Limited	Biomarker	[34]
Nervous system disease	DISJ7GGT	Limited	Biomarker	[35]
Parkinson disease	DISQVHKL	Limited	Genetic Variation	[36]
Prostate cancer	DISF190Y	Limited	Genetic Variation	[32]
Prostate carcinoma	DISMJPLE	Limited	Genetic Variation	[32]
Rheumatoid arthritis	DISTSB4J	Limited	Genetic Variation	[37]
Squamous cell carcinoma	DISQVIFL	Limited	Altered Expression	[3]

This DOT Affected the Drug Response of 2 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Cisplatin	DMRHGI9	Approved	Dystonin (DST) affects the response to substance of Cisplatin.	[67]
Fluorouracil	DMUM7HZ	Approved	Dystonin (DST) affects the response to substance of Fluorouracil.	[67]

6 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the methylation of Dystonin (DST).	[38]
Quercetin	DM3NC4M	Approved	Quercetin increases the phosphorylation of Dystonin (DST).	[45]
Fulvestrant	DM0YZC6	Approved	Fulvestrant increases the methylation of Dystonin (DST).	[50]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 decreases the phosphorylation of Dystonin (DST).	[45]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A increases the methylation of Dystonin (DST).	[62]
Coumarin	DM0N8ZM	Investigative	Coumarin decreases the phosphorylation of Dystonin (DST).	[45]

25 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Dystonin (DST).	[39]
Tretinoin	DM49DUI	Approved	Tretinoin decreases the expression of Dystonin (DST).	[40]
Acetaminophen	DMUIE76	Approved	Acetaminophen decreases the expression of Dystonin (DST).	[41]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate increases the expression of Dystonin (DST).	[42]
Estradiol	DMUNTE3	Approved	Estradiol increases the expression of Dystonin (DST).	[43]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Dystonin (DST).	[44]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide increases the expression of Dystonin (DST).	[46]
Vorinostat	DMWMPD4	Approved	Vorinostat decreases the expression of Dystonin (DST).	[47]
Progesterone	DMUY35B	Approved	Progesterone decreases the expression of Dystonin (DST).	[48]
Panobinostat	DM58WKG	Approved	Panobinostat decreases the expression of Dystonin (DST).	[49]
Folic acid	DMEMBJC	Approved	Folic acid decreases the expression of Dystonin (DST).	[51]
Bortezomib	DMNO38U	Approved	Bortezomib increases the expression of Dystonin (DST).	[52]
Irinotecan	DMP6SC2	Approved	Irinotecan decreases the expression of Dystonin (DST).	[53]
Indomethacin	DMSC4A7	Approved	Indomethacin decreases the expression of Dystonin (DST).	[54]
Melphalan	DMOLNHF	Approved	Melphalan decreases the expression of Dystonin (DST).	[55]
Clorgyline	DMCEUJD	Approved	Clorgyline increases the expression of Dystonin (DST).	[56]
Tamibarotene	DM3G74J	Phase 3	Tamibarotene decreases the expression of Dystonin (DST).	[40]
Seocalcitol	DMKL9QO	Phase 3	Seocalcitol increases the expression of Dystonin (DST).	[58]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the expression of Dystonin (DST).	[59]
Geldanamycin	DMS7TC5	Discontinued in Phase 2	Geldanamycin increases the expression of Dystonin (DST).	[60]
Torcetrapib	DMDHYM7	Discontinued in Phase 2	Torcetrapib increases the expression of Dystonin (DST).	[61]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A decreases the expression of Dystonin (DST).	[63]
Formaldehyde	DM7Q6M0	Investigative	Formaldehyde decreases the expression of Dystonin (DST).	[64]
GALLICACID	DM6Y3A0	Investigative	GALLICACID decreases the expression of Dystonin (DST).	[65]
4-hydroxy-2-nonenal	DM2LJFZ	Investigative	4-hydroxy-2-nonenal decreases the expression of Dystonin (DST).	[66]

1 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ximelegatran	DMU8ANS	Approved	Ximelegatran affects the localization of Dystonin (DST).	[57]

References

• [1] Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
• [2] Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new "B2" configuration of the RA-6 nuclear reactor.Radiat Environ Biophys. 2017 Nov;56(4):377-387. doi: 10.1007/s00411-017-0710-9. Epub 2017 Sep 4.
• [3] Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas.Clin Cancer Res. 2002 Apr;8(4):1127-38.
• [4] Mucus and adiponectin deficiency: role in chronic inflammation-induced colon cancer.Int J Colorectal Dis. 2013 Sep;28(9):1267-79. doi: 10.1007/s00384-013-1664-2. Epub 2013 Mar 9.
• [5] Dystonin/BPAG1 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis.Neurol Sci. 2019 Aug;40(8):1577-1582. doi: 10.1007/s10072-019-03879-3. Epub 2019 Apr 8.
• [6] The association of environmental toxicants and autism spectrum disorders in children.Environ Pollut. 2017 Aug;227:234-242. doi: 10.1016/j.envpol.2017.04.039. Epub 2017 May 2.
• [7] The effects of bisphenol A on some plasma cytokine levels and distribution of CD8(+) and CD4(+) T lymphocytes in spleen, ileal Peyer's patch and bronchus associated lymphoid tissue in rats.Acta Histochem. 2018 Nov;120(8):728-733. doi: 10.1016/j.acthis.2018.08.002. Epub 2018 Aug 11.
• [8] Construing the Biochemical and Molecular Mechanism Underlying the In Vivo and In Vitro Chemotherapeutic Efficacy of Ruthenium-Baicalein Complex in Colon Cancer.Int J Biol Sci. 2019 Apr 22;15(5):1052-1071. doi: 10.7150/ijbs.31143. eCollection 2019.
• [9] Genetic analysis of colon cancer susceptibility in mice.Genomics. 1994 Jul 15;22(2):381-7. doi: 10.1006/geno.1994.1399.
• [10] Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.Immunol Res. 2018 Oct;66(5):567-576. doi: 10.1007/s12026-018-9028-1.
• [11] Objective and Subjective Cognitive Problems among Caregivers and Matched Non-caregivers.Gerontologist. 2017 Aug 1;57(4):637-647. doi: 10.1093/geront/gnv690.
• [12] Characterization of gastrointestinal pathologies in the dystonia musculorum mouse model for hereditary sensory and autonomic neuropathy type VI.Neurogastroenterol Motil. 2020 Apr;32(4):e13773. doi: 10.1111/nmo.13773. Epub 2019 Dec 9.
• [13] Expanding the phenotype of DST-related disorder: A case report suggesting a genotype/phenotype correlation.Am J Med Genet A. 2017 Oct;173(10):2743-2746. doi: 10.1002/ajmg.a.38367. Epub 2017 Aug 2.
• [14] The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
• [15] Expression microarray analysis reveals alternative splicing of LAMA3 and DST genes in head and neck squamous cell carcinoma.PLoS One. 2014 Mar 27;9(3):e91263. doi: 10.1371/journal.pone.0091263. eCollection 2014.
• [16] Cortisol Secretion, Sensitivity, and Activity Are Associated With Hypertension in Postmenopausal Eucortisolemic Women.J Clin Endocrinol Metab. 2019 Oct 1;104(10):4441-4448. doi: 10.1210/jc.2019-00037.
• [17] The role of psychosocial and biological variables in separating chronic and non-chronic major depression and early-late-onset dysthymia.J Affect Disord. 1994 Sep;32(1):1-11. doi: 10.1016/0165-0327(94)90055-8.
• [18] Effects of perinatal exposure to BPA, BPF and BPAF on liver function in male mouse offspring involving in oxidative damage and metabolic disorder.Environ Pollut. 2019 Apr;247:935-943. doi: 10.1016/j.envpol.2019.01.116. Epub 2019 Jan 30.
• [19] Reexploring the possible roles of some genes associated with nasopharyngeal carcinoma using microarray-based detection.Acta Biochim Biophys Sin (Shanghai). 2005 Aug;37(8):541-6. doi: 10.1111/j.1745-7270.2005.00074.x.
• [20] Bisphenol A, phthalate metabolites and glucose homeostasis in healthy normal-weight children.Endocr Connect. 2018 Jan;7(1):232-238. doi: 10.1530/EC-17-0344. Epub 2017 Dec 13.
• [21] Evidence of association of the DISC1 interactome gene set with schizophrenia from GWAS.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Dec 20;95:109729. doi: 10.1016/j.pnpbp.2019.109729. Epub 2019 Aug 6.
• [22] Neurodegenerative disorders, bullous pemphigoid and psoriasis: a comparative study in ethnic Poles indicates that Parkinson's disease is more relevant to bullous pemphigoid.Postepy Dermatol Alergol. 2017 Feb;34(1):42-46. doi: 10.5114/ada.2017.65619. Epub 2017 Feb 7.
• [23] Bisphenol A modified DNA: A possible immunogenic stimulus for anti-DNA autoantibodies in systemic lupus erythematosus.Autoimmunity. 2019 Nov-Dec;52(7-8):272-280. doi: 10.1080/08916934.2019.1683545. Epub 2019 Oct 26.
• [24] Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients.Int J Tuberc Lung Dis. 2015 Feb;19(2):185-90. doi: 10.5588/ijtld.14.0651.
• [25] Bisphenol A induces human uterine leiomyoma cell proliferation through membrane-associated ER36 via nongenomic signaling pathways. Mol Cell Endocrinol. 2019 Mar 15;484:59-68. doi: 10.1016/j.mce.2019.01.001. Epub 2019 Jan 4.
• [26] Development of bullous pemphigoid in junctional epidermolysis bullosa.J Eur Acad Dermatol Venereol. 2020 Mar;34(3):e146-e148. doi: 10.1111/jdv.16057. Epub 2020 Feb 13.
• [27] Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer.Surg Today. 2019 Dec;49(12):1035-1043. doi: 10.1007/s00595-019-01842-5. Epub 2019 Jul 2.
• [28] BPAG1, a distinctive role in skin and neurological diseases.Semin Cell Dev Biol. 2017 Sep;69:34-39. doi: 10.1016/j.semcdb.2017.06.005. Epub 2017 Jun 13.
• [29] Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis?.Br J Dermatol. 2005 Mar;152(3):537-40. doi: 10.1111/j.1365-2133.2004.06338.x.
• [30] Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats.J Clin Invest. 2002 Feb;109(4):491-8. doi: 10.1172/JCI12858.
• [31] Impact of oxygen status on 10B-BPA uptake into human glioblastoma cells, referring to significance in boron neutron capture therapy.J Radiat Res. 2018 Mar 1;59(2):122-128. doi: 10.1093/jrr/rrx080.
• [32] Exposure to bisphenol A: current levels from food intake are toxic to human cells.Mol Biol Rep. 2019 Apr;46(2):2555-2559. doi: 10.1007/s11033-019-04666-1. Epub 2019 Feb 7.
• [33] The dexamethasone suppression test in bulimia: nonsuppression associated with depression and suboptimal weight.J Clin Psychiatry. 1988 Mar;49(3):94-6.
• [34] The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.Ann Surg. 2019 Oct;270(4):712-722. doi: 10.1097/SLA.0000000000003522.
• [35] Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid?.Eur J Dermatol. 2001 May-Jun;11(3):230-3.
• [36] Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.Mov Disord. 2012 Jul;27(8):1004-11. doi: 10.1002/mds.25005. Epub 2012 Apr 23.
• [37] Simultaneous evaluation of in vivo glucocorticoid sensitivity and expression of glucocorticoid receptor alpha-isoform in rheumatoid arthritis patients.Arq Bras Endocrinol Metabol. 2009 Feb;53(1):24-30. doi: 10.1590/s0004-27302009000100005.
• [38] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [39] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [40] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [41] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [42] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [43] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [44] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [45] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [46] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [47] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [48] Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
• [49] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [50] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [51] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [52] Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res. 2008 Feb;32(2):275-85. doi: 10.1016/j.leukres.2007.05.024. Epub 2007 Jul 19.
• [53] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [54] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
• [55] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [56] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [57] Myosin-mediated cytoskeleton contraction and Rho GTPases regulate laminin-5 matrix assembly. Cell Motil Cytoskeleton. 2004 Feb;57(2):107-17. doi: 10.1002/cm.10161.
• [58] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [59] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [60] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [61] Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol. 2012 Dec 10;6:152.
• [62] Expression and DNA methylation changes in human breast epithelial cells after bisphenol A exposure. Int J Oncol. 2012 Jul;41(1):369-77.
• [63] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [64] Gene expression changes in primary human nasal epithelial cells exposed to formaldehyde in vitro. Toxicol Lett. 2010 Oct 5;198(2):289-95.
• [65] Gene expression profile analysis of gallic acid-induced cell death process. Sci Rep. 2021 Aug 18;11(1):16743. doi: 10.1038/s41598-021-96174-1.
• [66] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [67] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.